{"address1": "777 Old Saw Mill River Road", "city": "Tarrytown", "state": "NY", "zip": "10591-6707", "country": "United States", "phone": "914 847 7000", "website": "https://www.regeneron.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia (HoFH) or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; Evkeeza for treatment of HoFH; Ordspono for Follicular lymphoma and Diffuse large B-cell lymphoma; and Veopoz for CD55-deficient protein-losing enteropathy. Further, it develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc. to discover, develop, and commercialize engineered regulatory T cell therapies. The company was incorporated in 1988 and is headquartered in Tarrytown, New York.", "fullTimeEmployees": 15182, "companyOfficers": [{"maxAge": 1, "name": "Dr. Leonard S. Schleifer M.D., Ph.D.", "age": 71, "title": "Co-Founder, President, CEO & Co-Chairman", "yearBorn": 1953, "fiscalYear": 2024, "totalPay": 6823034, "exercisedValue": 117275128, "unexercisedValue": 192379808}, {"maxAge": 1, "name": "Dr. George D. Yancopoulos M.D., Ph.D.", "age": 64, "title": "Co-Founder, President, Chief Scientific Officer & Co-Chairman", "yearBorn": 1960, "fiscalYear": 2024, "totalPay": 6796783, "exercisedValue": 95717904, "unexercisedValue": 188321072}, {"maxAge": 1, "name": "Mr. Christopher R. Fenimore CPA", "age": 53, "title": "Executive VP of Finance & CFO", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 1269250, "exercisedValue": 9054700, "unexercisedValue": 16618295}, {"maxAge": 1, "name": "Dr. Andrew J. Murphy Ph.D.", "age": 66, "title": "Executive Vice President of Research", "yearBorn": 1958, "fiscalYear": 2024, "totalPay": 1613560, "exercisedValue": 26279800, "unexercisedValue": 56244512}, {"maxAge": 1, "name": "Mr. Daniel P. Van Plew", "age": 51, "title": "Executive VP and GM of Industrial Operations & Product Supply", "yearBorn": 1973, "fiscalYear": 2024, "totalPay": 1905481, "exercisedValue": 20283170, "unexercisedValue": 9502018}, {"maxAge": 1, "name": "Mr. Rajesh  Ahuja", "title": "Senior Vice President of Quality Assurance & Operations", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Bob  McCowan", "title": "Senior VP of IT & Chief Information Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Ryan  Crowe", "title": "Senior Vice President of Investor Relations & Strategic Analysis", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Joseph J. LaRosa J.D.", "age": 65, "title": "Executive VP, General Counsel & Secretary", "yearBorn": 1959, "fiscalYear": 2024, "totalPay": 1748110, "exercisedValue": 23227300, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Melissa  Lozner", "title": "Senior VP & Chief Compliance Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 8, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 10, "overallRisk": 10, "governanceEpochDate": 1754006400, "compensationAsOfEpochDate": 1735603200, "irWebsite": "http://newsroom.regeneron.com/", "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 559.8, "open": 559.74, "dayLow": 558.0618, "dayHigh": 567.69, "regularMarketPreviousClose": 559.8, "regularMarketOpen": 559.74, "regularMarketDayLow": 558.0618, "regularMarketDayHigh": 567.69, "dividendRate": 3.52, "dividendYield": 0.63, "exDividendDate": 1755475200, "payoutRatio": 0.0444, "beta": 0.327, "trailingPE": 14.184934, "forwardPE": 12.425512, "volume": 1024292, "regularMarketVolume": 1024292, "averageVolume": 1200535, "averageVolume10days": 1009480, "averageDailyVolume10Day": 1009480, "bid": 562.43, "ask": 564.42, "bidSize": 2, "askSize": 2, "marketCap": 59670679552, "fiftyTwoWeekLow": 476.49, "fiftyTwoWeekHigh": 1211.2, "priceToSalesTrailing12Months": 4.1979623, "fiftyDayAverage": 537.5858, "twoHundredDayAverage": 654.85095, "trailingAnnualDividendRate": 1.76, "trailingAnnualDividendYield": 0.00314398, "currency": "USD", "tradeable": false, "enterpriseValue": 53611528192, "profitMargins": 0.31367, "floatShares": 97911015, "sharesOutstanding": 104170000, "sharesShort": 2074491, "sharesShortPriorMonth": 2031432, "sharesShortPreviousMonthDate": 1749772800, "dateShortInterest": 1752537600, "sharesPercentSharesOut": 0.0195, "heldPercentInsiders": 0.01935, "heldPercentInstitutions": 0.93677, "shortRatio": 2.06, "shortPercentOfFloat": 0.020599999, "impliedSharesOutstanding": 105987000, "bookValue": 287.55, "priceToBook": 1.9579204, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1751241600, "earningsQuarterlyGrowth": -0.028, "netIncomeToCommon": 4458599936, "trailingEps": 39.69, "forwardEps": 45.31, "enterpriseToRevenue": 3.772, "enterpriseToEbitda": 12.002, "52WeekChange": -0.49781018, "SandP52WeekChange": 0.19554341, "lastDividendValue": 0.88, "lastDividendDate": 1747699200, "quoteType": "EQUITY", "currentPrice": 563.0, "targetHighPrice": 815.0, "targetLowPrice": 543.0, "targetMeanPrice": 708.9068, "targetMedianPrice": 740.0, "recommendationMean": 1.83333, "recommendationKey": "buy", "numberOfAnalystOpinions": 22, "totalCash": 7469599744, "totalCashPerShare": 72.04, "ebitda": 4466800128, "totalDebt": 2705100032, "quickRatio": 3.567, "currentRatio": 4.598, "totalRevenue": 14214200320, "debtToEquity": 9.035, "revenuePerShare": 133.029, "returnOnAssets": 0.06656, "returnOnEquity": 0.15336001, "grossProfits": 6730500096, "freeCashflow": 2850962432, "operatingCashflow": 4743499776, "earningsGrowth": 0.032, "revenueGrowth": 0.036, "grossMargins": 0.47351003, "ebitdaMargins": 0.31425, "operatingMargins": 0.29641, "financialCurrency": "USD", "symbol": "REGN", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 670602600000, "longName": "Regeneron Pharmaceuticals, Inc.", "marketState": "CLOSED", "shortName": "Regeneron Pharmaceuticals, Inc.", "corporateActions": [{"header": "Dividend", "message": "REGN announced a cash dividend of 0.88 with an ex-date of Aug. 18, 2025", "meta": {"eventType": "DIVIDEND", "dateEpochMs": 1755489600000, "amount": "0.88"}}], "postMarketTime": 1754696922, "regularMarketTime": 1754683200, "exchange": "NMS", "messageBoardId": "finmb_33715", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 0.571635, "regularMarketPrice": 563.0, "epsTrailingTwelveMonths": 39.69, "epsForward": 45.31, "epsCurrentYear": 39.46901, "priceEpsCurrentYear": 14.264356, "fiftyDayAverageChange": 25.414185, "fiftyDayAverageChangePercent": 0.047274657, "twoHundredDayAverageChange": -91.85095, "twoHundredDayAverageChangePercent": -0.14026238, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.8 - Buy", "cryptoTradeable": false, "postMarketChangePercent": -2.3055, "postMarketPrice": 550.02, "postMarketChange": -12.98, "regularMarketChange": 3.20001, "regularMarketDayRange": "558.0618 - 567.69", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1200535, "fiftyTwoWeekLowChange": 86.51001, "fiftyTwoWeekLowChangePercent": 0.18155682, "fiftyTwoWeekRange": "476.49 - 1211.2", "fiftyTwoWeekHighChange": -648.19995, "fiftyTwoWeekHighChangePercent": -0.5351717, "fiftyTwoWeekChangePercent": -49.781017, "dividendDate": 1756857600, "earningsTimestamp": 1754051400, "earningsTimestampStart": 1761827400, "earningsTimestampEnd": 1761827400, "earningsCallTimestampStart": 1754051400, "earningsCallTimestampEnd": 1754051400, "isEarningsDateEstimate": true, "displayName": "Regeneron Pharmaceuticals", "trailingPegRatio": 1.153}